Theravance Biopharma, Inc. Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
Theravance Biopharma, Inc. (TBPH) reported Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions of $632.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-07.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions · last filed 2025-03-07
- Theravance Biopharma, Inc. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2023 was $632.00K, a 91.45% decline from fiscal 2022.
- Theravance Biopharma, Inc. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2022 was $7.39M, a 1772.15% increase from fiscal 2021.
- Theravance Biopharma, Inc. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2021 was $395.00K, a 95.10% decline from fiscal 2020.
- Theravance Biopharma, Inc. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2020 was $8.06M, a 300.95% increase from fiscal 2019.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 12 month |
|---|---|
| 2023-12-31 | $632.00K 10-K · filed 2025-03-07 |
| 2022-12-31 | $7.39M 10-K · filed 2024-03-01 |
| 2021-12-31 | $395.00K 10-K · filed 2023-03-01 |
| 2020-12-31 | $8.06M 10-K · filed 2022-02-28 |
| 2019-12-31 | $2.01M 10-K · filed 2021-02-26 |
| 2018-12-31 | $685.00K 10-K · filed 2019-02-28 |
| 2017-12-31 | $51.00K 10-K · filed 2018-02-28 |
| 2014-12-31 | $0.00 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |